Skip to main content
Erschienen in: Medical Oncology 3/2010

01.09.2010 | Original paper

Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B

verfasst von: Alessandro Allegra, Giuseppa Penna, Andrea Alonci, Angela Granata, Arianna D’Angelo, Caterina Musolino

Erschienen in: Medical Oncology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Immune thrombocytopenia is a disease mediated by platelet autoantibodies that accelerate platelet destruction and inhibit their production. Most cases are considered idiopathic, whereas others are secondary to coexisting conditions such as infectious diseases. All hepatotropic viruses seem able to cause thrombocytopenia. The advent of molecular techniques has revealed the possible persistence of hepatitis B virus genome in HBsAg-negative individuals with or without serologic markers of previous infection. This form of infection is named occult. We report a case of autoimmune thrombocytopenia associated with acute reverse seroconversion of hepatitis B in a patient who was initially hepatitis B virus surface antigen negative and hepatitis B virus surface antibody positive. The search for occult HBV infection before immunosuppressive therapy and monitoring for reactivation is today diagnostic standard and several reports have been presented in literature about HBV reactivation following immunosuppressive therapy. In our patient, reactivation of dormant HBV happened prior to any immunosuppressive therapy. The case we report offers the occasion to emphasize the importance of medium-term and long-term hemovigilance also in other kind of patients than in subjects on immunosuppressive therapy. A deeper follow-up is advisable even in patients showing an unexplainable worsening of their hematological conditions.
Literatur
1.
Zurück zum Zitat Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113:6511–21.CrossRefPubMed Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113:6511–21.CrossRefPubMed
2.
Zurück zum Zitat Michalska Z, et al. Autoimmune reactions in HBV and HCV. Med Sci Monit. 2001;7(Suppl 1):175–80.PubMed Michalska Z, et al. Autoimmune reactions in HBV and HCV. Med Sci Monit. 2001;7(Suppl 1):175–80.PubMed
3.
Zurück zum Zitat Douglas B, et al. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;26:6511–21. Douglas B, et al. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;26:6511–21.
4.
Zurück zum Zitat Tanir G, Aydemir C, Tuygun N, Kaya O, Yarali N. Immune thrombocytopenic purpura as sole manifestation in a case of acute hepatitis A. Turk J Gastroenterol. 2005;4:217–9. Tanir G, Aydemir C, Tuygun N, Kaya O, Yarali N. Immune thrombocytopenic purpura as sole manifestation in a case of acute hepatitis A. Turk J Gastroenterol. 2005;4:217–9.
5.
Zurück zum Zitat Thapa R, Mallick D, Ghosh A. Childhood hepatitis E infection complicated by acute immune thrombocytopenia. J Pediatr Hematol Oncol. 2009;31(2):151.CrossRefPubMed Thapa R, Mallick D, Ghosh A. Childhood hepatitis E infection complicated by acute immune thrombocytopenia. J Pediatr Hematol Oncol. 2009;31(2):151.CrossRefPubMed
6.
Zurück zum Zitat Kim EB et al. Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy. Cancer Res Treat. 2008; 40:1, 36. Kim EB et al. Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy. Cancer Res Treat. 2008; 40:1, 36.
7.
Zurück zum Zitat Geier DA, Geier MR. A case–control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005;38(4):295–301.CrossRefPubMed Geier DA, Geier MR. A case–control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005;38(4):295–301.CrossRefPubMed
8.
Zurück zum Zitat Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the vaccine adverse event reporting system (VAERS) database and literature review. Clin Exp Rheumatol. 2004;22(6):749–55.PubMed Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the vaccine adverse event reporting system (VAERS) database and literature review. Clin Exp Rheumatol. 2004;22(6):749–55.PubMed
9.
Zurück zum Zitat Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection? The Lancet. 2005;365:638–9. Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection? The Lancet. 2005;365:638–9.
10.
Zurück zum Zitat Raimondo G, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652–7.CrossRefPubMed Raimondo G, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652–7.CrossRefPubMed
11.
Zurück zum Zitat Kitano K, et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol. 2006;77:255–8.CrossRefPubMed Kitano K, et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol. 2006;77:255–8.CrossRefPubMed
12.
Zurück zum Zitat Raimondo G, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol. 2008;48:743–6.CrossRefPubMed Raimondo G, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol. 2008;48:743–6.CrossRefPubMed
13.
Zurück zum Zitat Aubourg A, d’Alteroche L, Senecal D, Gaudy C, Bacq Y. Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation. Gastroenterol Clin Biol. 2007;31(1):97–99. Aubourg A, d’Alteroche L, Senecal D, Gaudy C, Bacq Y. Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation. Gastroenterol Clin Biol. 2007;31(1):97–99.
14.
Zurück zum Zitat Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Int Med Journal. 2007;37:705–12. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Int Med Journal. 2007;37:705–12.
15.
Zurück zum Zitat Iannacone M, Sitia G, Ruggeri ZM, Guidot LG. HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol. 2007;46(4):719–26.CrossRefPubMed Iannacone M, Sitia G, Ruggeri ZM, Guidot LG. HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol. 2007;46(4):719–26.CrossRefPubMed
Metadaten
Titel
Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B
verfasst von
Alessandro Allegra
Giuseppa Penna
Andrea Alonci
Angela Granata
Arianna D’Angelo
Caterina Musolino
Publikationsdatum
01.09.2010
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9305-x

Weitere Artikel der Ausgabe 3/2010

Medical Oncology 3/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.